Astel­las, Pan­th­er­na add or­gan to mR­NA tie-up; Rock­et launch­es sale of six fig­ures worth of stock

Astel­las and Pan­th­er­na have ex­pand­ed their No­vem­ber 2021 pact sur­round­ing the lat­ter’s mR­NA plat­form to in­clude a new tar­get or­gan, the duo an­nounced Tues­day morn­ing, though they did not spec­i­fy what that tar­get is.

Ger­man biotech Pan­th­er­na is home to two plat­form tech­nolo­gies — one that de­signs mR­NAs for non-vac­cine ther­a­pies and an­oth­er that de­signs LNPs. Astel­las and Pan­th­er­na’s deal ap­pears to main­ly re­volve around the first plat­form, which Astel­las said it is us­ing to re­search di­rect re­pro­gram­ming, or turn­ing cells from one kind in­to an­oth­er with­out an in­ter­me­di­ate stem cell phase.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER